Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;18(6):e110522204572.
doi: 10.2174/1573403X18666220511114443.

Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease

Jonathan C H Chan  1   2 , Michael C Y Chan  1
Affiliations
Review

Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease

Jonathan C H Chan et al. Curr Cardiol Rev. 2022.

Abstract

Background: Diabetes is a major risk factor for developing cardiovascular disease. Patients with both diabetes and cardiovascular disease have even higher mortality. The convergence of cardiology and diabetology therapy is an important step in treating patients and advancing research.

Results: Major landmark trials and meta-analyses involving Sodium Glucose Cotransporter 2 inhibitors have shown dramatic clinical cardiorenal benefits in patients both with and without type 2 diabetes. In type 2 diabetes patients, Glucagon-like peptide-1 receptor agonists have been shown to improve major cardiac outcomes.

Conclusion: This hot topic of research and clinical use of glucose lowering drugs intersects the fields of cardiovascular, renal, and diabetic medicine. The numerous cardiorenal benefits have led to the rapid adoption in clinical guidelines of these glucose lowering drugs in patients with Type 2 diabetes, cardiovascular disease, or renal disease.

Keywords: Cardiovascular disease; GLP-1 receptor agonist; SGLT2 inhibitor; cardiorenal protection; cardiovascular outcome trial; chronic kidney disease; diabetes; heart failure.

PubMed Disclaimer

References

    1. Rana J.S., Khan S.S., Lloyd-Jones D.M., Sidney S. Changes in mortality in top 10 causes of death from 2011 to 2018. J. Gen. Intern. Med. 2020 doi: 10.1007/s11606-020-06070-z. - DOI - PMC - PubMed
    1. Cho N.H., Shaw J.E., Karuranga S., et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res. Clin. Pract. 2018;138:271–281. doi: 10.1016/j.diabres.2018.02.023. - DOI - PubMed
    1. Di Angelantonio E., Kaptoge S., Wormser D., et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314(1):52–60. doi: 10.1001/jama.2015.7008. - DOI - PMC - PubMed
    1. O’Meara E., McDonald M., Chan M., et al. CCS/CHFS heart failure guidelines: Clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can. J. Cardiol. 2020;36(2):159–169. doi: 10.1016/j.cjca.2019.11.036. - DOI - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi: 10.1016/S0140-6736(98)07019-6. - DOI - PubMed

MeSH terms

Substances